Neuroendocrine tumor registry results post arm-level phase 2 outcomes

원문 링크: WordPress 원문

ClinicalTrials.gov posted registry results on 28 August 2026 for 32 adults with well-differentiated neuroendocrine tumors and symptomatic or progressive metastases , including a 0.35 overall response-rate value in the 26-person pembrolizumab plus PRRT group . The non-randomized pilot used three unequal treatment groups and the result is registry-posted rather than peer-reviewed , while the entry makes the protocol-defined outcomes and arm-level safety reporting publicly inspectable .

The registry first posted these results on 28 August 2026, creating a new official record for this completed phase 2 trial.

32 enrolled Actual registry enrollment Official record

26 in main arm Participant-flow count Official record

0.35 reported Arm-level ORR value Official record

ENGKOR

AI-generated conceptual illustration; not study data.

Registry results separate the three treatment groups

ClinicalTrials.gov describes an interventional phase 2 pilot that paired pembrolizumab with one of three liver-directed approaches. Actual enrollment was 32 people. The participant-flow record lists 26 people in the pembrolizumab plus peptide receptor radionuclide therapy, or PRRT, group, and three people in each of the two smaller liver-directed groups. Those numbers matter because the registry reports outcomes separately, not as one pooled estimate.

Design: non-randomized, parallel phase 2 pilot. Enrolled: 32 adults. Analysis: arm-specific results; main PRRT arm had 26 participants. Primary endpoint: investigator-reported RECIST 1.1 overall response rate.

The reported 0.35 value belongs to the 26-person pembrolizumab plus PRRT group, not to all 32 enrolled people and not to the two three-person groups. The registry defines the endpoint as best observed overall response by investigator report. Overall response rate is the share of an analysis group with a complete or partial response under the stated assessment rule.

A non-randomized parallel pilot can describe what happened within each planned group, but it does not assign people at random or provide a balanced head-to-head test of the treatment approaches. The public result therefore supports careful description of the registry entry, not a claim that one approach caused a better outcome.

A public registry result is useful before it becomes a treatment conclusion

Neuroendocrine tumors can involve the liver and may be managed with systemic treatment, receptor-targeted radionuclide treatment, or liver-directed procedures. This protocol combined pembrolizumab with different approaches selected around clinical circumstances. That is a clinically interesting question, but the registry entry is not a comparison that can settle which combination should be preferred.

The newly posted record is still useful because it places the protocol, group descriptions, outcome definitions, and reported arm-level values in one official location. Readers can see that the trial was completed and that the endpoint was investigator-reported RECIST 1.1 rather than assume that a registry posting is the same as a journal publication. It also makes later peer-reviewed reporting easier to check against the original registered plan.

For patients and clinicians, the practical interpretation is narrow: the record documents results from a small completed pilot and identifies where the reported response value belongs. It does not establish a standard regimen, prove benefit over another option, or tell an individual patient what outcome to expect. Those questions require broader evidence, clinical context, and professional care.

AI-generated conceptual illustration; not study data.

Small groups and registry reporting set firm limits

The three groups are markedly unequal. A value from a group of 26 should not be read with the same certainty as a value from a group of three, and neither can be treated as a randomized comparison. The registry also records that two of the liver-directed groups were closed. It does not turn the entry into a final account of why treatment choices were made for every participant.

The results modules include adverse-event reporting by group, but safety interpretation needs the same discipline as efficacy interpretation. Events in people with advanced disease may have several possible contributors, and a registry table alone does not prove attribution, frequency in routine care, or a favorable benefit-risk balance. The official record should be read alongside its defined analysis population and reporting framework.

The safety scope here is arm-specific registry reporting, not a claim that the combination is safe for all people with neuroendocrine tumors. Small cohorts, differing procedures, disease severity, and incomplete contextual detail limit any broad inference. Decisions about cancer treatment need an oncology team that can weigh alternatives, prior therapies, organ function, and monitoring needs.

AI-generated conceptual illustration; not study data.

The next evidence should clarify durability and comparison

The most useful next report would explain the analysis sets, follow-up, response confirmation, reasons for group closure, and how adverse events were attributed. A peer-reviewed paper can add methods and context that a registry result table cannot carry. If later work compares approaches, the comparison should make its eligibility criteria and denominators explicit.

For now, the change is straightforward: a completed trial has a newly public official results record. The record gives readers something concrete to inspect, but it leaves major clinical questions open. A registry number is a starting point for evidence review, not a prescription.

That distinction can feel technical, yet it protects against a common misunderstanding. A public result table can show a planned endpoint and an observed arm-level value without showing whether another regimen would have produced the same result in similar people. It also cannot substitute for a conversation about eligibility, prior treatment, imaging review, or the practical burden of a therapy. The registry does not need to be dismissed for those reasons. It should be read for what it is: a transparent official record that permits scrutiny, preserves the original protocol context, and signals which questions remain for a fuller report. Readers following later coverage can return to this entry to check whether the denominators, endpoints, and safety descriptions remain aligned.

Evidence boundary. This article reports an official ClinicalTrials.gov registry entry. The entry is a completed, non-randomized phase 2 pilot with unequal groups. Registry-posted outcomes do not by themselves establish comparative efficacy, routine-care safety, regulatory approval, or an individual treatment recommendation. References

• ClinicalTrials.gov: NCT03457948 official study record and results.

This article is for general information and is not medical advice. Discuss diagnosis and treatment choices with qualified clinicians.